(IN BRIEF) Fresenius Kabi, in partnership with Formycon AG, has received European Commission approval for Otulfi®, a biosimilar of ustekinumab. This new product, authorized for both subcutaneous and intravenous formulations, will treat inflammatory conditions such as Crohn’s disease, plaque psoriasis, … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Dr. Sang-Jin Pak, Formycon AG, Fresenius Kabi, inflammatory diseases, Otulfi®, partnership, safety, sustainability, Ustekinumab Biosimilar
(IN BRIEF) Fresenius Kabi announces FDA approval of Tyenne® (tocilizumab-aazg), the first tocilizumab biosimilar offering both IV and subcutaneous formulations. This marks a significant milestone in the company’s growth strategy (#FutureFresenius) and expands treatment options for inflammatory, autoimmune diseases, and … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech
Tagged #FutureFresenius, Actemra®, autoimmune diseases, Biosimilar, Cancer, cancer treatment, FDA, Food and Drug Administration, Fresenius Kabi, Genentech, Idacio®, inflammatory, inflammatory diseases, IV, IV formulation, Stimufend®, Subcutaneous formulation, subcutaneous tocilizumab biosimilar, tocilizumab, tocilizumab biosimilar, tocilizumab-aazg, Tyenne®
(PRESS RELEASE) SANOFI, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced an exclusive worldwide collaboration agreement signed with IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and … Read the full press release
These collaborations are in response to the calls for innovation via AlmirallShare, the open innovation platform of Almirall and aim to identify new biosignatures and treatments for skin cancer and atopic dermatitis AlmirallShare is responsible for 50% of the private-public … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Spain
Tagged Almirall, AlmirallShare, atopic dermatitis, dermatological conditions, dermatological research, Dermatology, Dublin City University, Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, IDIBAPS, inflammatory diseases, Maribel Crespo, medical dermatology, molecular mechanisms, open innovation platform, Prof. Dr. Lluís Puig, Prof. Silvia Vidal, Prof. Tarl Prow, skin cancer, skin carcinoma, skin health, skin immune cell composition, skin transcriptome, skin tumor, Squamous cell Carcinoma, systemic biomarkers, systemic therapy, topical drugs, University College Dublin, University of Namur, University of Sheffield, University of South Australia, University of Turin
Ghent, Belgium, 12-6-2014 — /EuropaWire/ — Researchers at VIB and Ghent University have unraveled the mechanism of necroptosis. This is a type of cell death that plays a crucial role in numerous diseases such as viral infections, multiple sclerosis, acute heart … Read the full press release
Posted in Belgium, Education, Healthcare, Science
Tagged Amanda Goncalves, Clark A. Sehon, Ghent University, inflammatory diseases, Inge Bruggeman, Jean-Claude Martinou, John Bertin, Kathrin Weber, Mathieu J.M. Bertrand, mechanism of necroptosis, Paco Hulpiau, perspectives for treating degenerative, Peter J. Gough, Peter Vandenabeele, Ria Roelandt, Robert W. Marquis, Savvas Savvides, Sylvie Montessuit, VIB, Wim Declercq, Yves Dondelinger
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?